Back to top
more

Neogen (NEOG)

(Real Time Quote from BATS)

$4.69 USD

4.69
3,152,050

+0.03 (0.64%)

Updated Aug 4, 2025 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Neogen (NEOG) give insight into how the company performed in the quarter ended May 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Neogen (NEOG) Q4 Earnings Lag Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -37.50% and +1.90%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Neogen Stock Gains Following Strategic Alliance With Syngenta

by Zacks Equity Research

NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.

Zacks Equity Research

Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Neogen (NEOG) Up 6.4% Since Last Earnings Report?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Company News for Apr 10, 2025

by Zacks Equity Research

Companies in The News Are: DAL,AMPL,NEOG,GM

Zacks Equity Research

Neogen Stock Tumbles on Q3 Earnings & Sales Miss, Margins Contract

by Zacks Equity Research

NEOG posts lower-than-expected earnings and revenues for the third quarter of fiscal 2025.

Zacks Equity Research

Neogen (NEOG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended February 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -23.08% and 0.92%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seeking Clues to Neogen (NEOG) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Neogen (NEOG) for the quarter ended February 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Moumi Mondal headshot

Should You Bet on PAHC Stock at a Discounted P/E of 10.41X?

by Moumi Mondal

PAHC's solid MFA franchise, now bolstered by Zoetis' portfolio, makes it a solid investment case. A well-established foothold in key regions is also a factor.

Zacks Equity Research

Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 0% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit

by Zacks Equity Research

Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources.

Zacks Equity Research

NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls

by Zacks Equity Research

NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings Match Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exploring Analyst Estimates for Neogen (NEOG) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Neogen (NEOG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended November 2024.

Zacks Equity Research

Macroeconomic Woes, FX Headwind Drag NEOG Stock Down

by Zacks Equity Research

NEOG faces intense competition due to the development of new technologies by competitors, which could affect the marketability and profitability of its products.

Zacks Equity Research

NEOG Stock Gains From New Addition to the Petrifilm Product Line

by Zacks Equity Research

Neogen expands the Petrifilm product line with the introduction of Petrifilm Bacillus cereus Count Plate.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -800% and 6.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock

by Zacks Equity Research

NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.

Zacks Equity Research

Neogen Q1 Earnings Miss Estimates, Margins Crash

by Zacks Equity Research

NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.

Zacks Equity Research

Company News for Oct 11, 2024

by Zacks Equity Research

Companies in The News Are: DAL,DPZ,NEOG,TXG